IP Library Granted Patent US 7,226,774
Granted Patent B2
US 7,226,774 · App. 10/366,630 · Granted Jun 5, 2007

Signal for packaging of influenza virus vectors

Assignee: Wisconsin Alumni Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,226,774
App. No.
10/366,630
Granted
Jun 5, 2007
Kind
B2
Abstract

The invention provides a packaging (incorporation) signal for influenza virus vectors, and methods of using the signal to transmit and maintain influenza viral and foreign nucleic acid in virus and cells.

Claims (29)

1. An influenza viral vector, comprising influenza virus incorporation sequences, which vector comprises:

sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the NA coding sequences which include 3′ NA incorporation sequences include at least 90 nucleotides of 5′ NA coding sequence and the NA coding sequences which include 5′ NA incorporation sequences have no more than 157 nucleotides of 3′ NA coding sequences.

2. The vector of claim 1 wherein the heterologous nucleic acid segment comprises sequences corresponding to an internal ribosome entry sequence.

3. The vector of claim 1 wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for a marker gene.

4. The vector of claim 1 wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for an immunogenic protein or a peptide of a pathogen, or a therapeutic protein.

5. The vector of claim 1 wherein incorporation sequences are from a type A influenza virus.

6. An influenza viral vector, comprising influenza virus incorporation sequences, which vector comprises:

sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the incorporation sequences are from a type B influenza virus.

7. The vector of claim 1 wherein the heterologous nucleic acid segment is fused to another nucleic acid segment so as to encode a fusion protein.

8. A recombinant influenza virus comprising a vRNA corresponding to the vector of claim 1 .

9. The recombinant virus of claim 8 wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for a marker gene.

10. The recombinant virus of claim 8 wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for an immunogenic protein or peptide of a pathogen.

11. A recombinant influenza virus comprising a vRNA corresponding to influenza viral vector sequences comprising: sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the open reading frame encodes an influenza virus HA protein.

12. The recombinant virus of claim 10 wherein the open reading frame encodes an influenza virus NA protein.

13. A recombinant influenza virus comprising a vRNA corresponding to influenza vital vector sequences comprising: sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for a transmembrane protein.

14. A recombinant influenza virus comprising a vRNA corresponding to influenza viral vector sequences comprising:

sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for a protein with membrane fusing activity.

15. A recombinant influenza virus comprising a vRNA corresponding to influenza vial vector sequences comprising: sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for a viral capsid protein.

16. A recombinant influenza virus comprising a vRNA corresponding to influenza viral vector sequences comprising: sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the heterologous nucleic acid segment comprises sequences corresponding to an open reading frame for vesicular stomatitis virus G protein.

17. A recombinant influenza virus comprising a vRNA corresponding to influenza viral vector sequences comprising:, sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA, coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the 3′ NA incorporation sequences include at least 150 nucleotides of NA coding sequences, wherein the heterologous nucleic acid segment comprises sequences corresponding to an 'open reading frame for a therapeutic protein.

18. The recombinant virus of 11 wherein the influenza virus HA protein is a type B HA protein.

19. A method to express a heterologous nucleic acid segment in a cell, comprising: contacting a cell with the recombinant virus of claim 8 and detecting or determining whether a product encoded by the heterologous nucleic acid segment is expressed in the cell.

20. A vector comprising sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the NA coding sequences which include 3′ NA incorporation sequences include at least 90 nucleotides of 5′ NA coding sequence and the NA coding sequences which include 5′ NA incorporation sequences have no more than 157 nucleotides of 3′ NA coding sequences.

21. The vector of claim 1 wherein vRNA corresponding to the vector, when present in the cell, is packaged into virions at an efficiency at least 10% that of a corresponding wild-type vRNA.

22. The vector of claim 1 wherein vRNA corresponding to the vector, when present in the cell, is packaged into virions at an efficiency at least 30% that of a corresponding wild-type vRNA.

23. The vector of claim 1 wherein vRNA corresponding to the vector, when present in the cell, is packaged into virions at an efficiency at least 60% that of a corresponding wild-type vRNA.

24. The vector of claim 1 wherein the sequences corresponding to the open reading frame are operably linked to the sequences corresponding to NA coding sequences which include 3′ NA incorporation sequences so as to yield sequences corresponding to those which encode a fusion protein comprising NA sequences and the gene product.

25. A vector comprising sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA-incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the NA coding sequences which include the 3′ NA incorporation sequences have no more than 183 nucleotides of 5′ NA coding sequence and the NA coding sequences which include the 5′ NA incorporation sequences have at least 39 nucleotides of 3′ NA coding sequence, wherein the vector does not encode a functional NA.

26. An influenza viral vector, comprising influenza virus incorporation sequences, which vector comprises: sequences corresponding to the 3′ noncoding region of influenza virus NA vRNA and NA coding sequences which include 3′ NA incorporation sequences, a nucleic acid segment for a heterologous open reading frame which encodes a gene product, and NA coding sequences which include 5′ NA incorporation sequences and the 5′ noncoding region of NA vRNA, wherein the NA coding sequences which include the 3′ NA incorporation sequences have no more than 183 nucleotides of 5′ NA coding sequence and the NA coding sequences which include the 5′ NA incorporation sequences have at least 39 nucleotides of 3′ NA coding sequence, wherein the vector does not encode a functional NA.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 18, 2008
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022003/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2003
From: KAWAOKA, YOSHIHIRO
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 013805/0918 →
Continuity (3)
Provisional Application 6035653800 · Feb 13, 2002
Provisional Application 6043867900 · Jan 7, 2003
Related Publication 20040002061A1 · Jan 1, 2004